Vertex Pharma (VRTX) Tops Q3 EPS by 5c; bumps guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Oil jumps on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $524.52 --0%
Revenue Growth %: +10.7%
Financial Fact:
Net loss: -39.54M
Today's EPS Names:
SICP, MNSB, CFFI, More
Revenue Growth %: +10.7%
Financial Fact:
Net loss: -39.54M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $3.97, $0.05 better than the analyst estimate of $3.92. Revenue for the quarter came in at $2.48 billion versus the consensus estimate of $2.5 billion.
GUIDANCE:
Vertex Pharma sees FY2023 revenue of $9.85 billion, versus prior guidance of $9.7-$9.8 billion and consensus of $9.87 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Roper Technologies (ROP) Tops Q3 EPS by 10c ; Offers Guidance
- SK Hynix could join the Nasdaq 100 if it expands its ADR float: Goldman
- Norfolk Southern (NSC) Tops Q3 EPS by 14c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
